Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Several lines of evidence are indicative of a role for immune activation in the pathophysiology of schizophrenia. Nevertheless, studies using positron emission tomography (PET) and radioligands for the translocator protein (TSPO), a marker for glial activation, have yielded inconsistent results. Whereas early studies using a radioligand with low signal-to-noise in small samples showed increases in patients, more recent studies with improved methodology have shown no differences or trend-level decreases. Importantly, all patients investigated thus far have been on antipsychotic medication, and as these compounds may dampen immune cell activity, this factor limits the conclusions that can be drawn. Here, we examined 16 drug-naive, first-episode psychosis patients and 16 healthy controls using PET and the TSPO radioligand [11C]PBR28. Gray matter (GM) volume of distribution (VT) derived from a two-tissue compartmental analysis with arterial input function was the main outcome measure. Statistical analyses were performed controlling for both TSPO genotype, which is known to affect [11C]PBR28 binding, and gender. There was a significant reduction of [11C]PBR28 VT in patients compared with healthy controls in GM as well as in secondary regions of interest. No correlation was observed between GM VT and clinical or cognitive measures after correction for multiple comparisons. The observed decrease in TSPO binding suggests reduced numbers or altered function of immune cells in brain in early-stage schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742
Zhan, Y., Paolicelli, R. C., Sforazzini, F., Weinhard, L., Bolasco, G., Pagani, F., Vyssotski, A. L., Bifone, A., Gozzi, A., Ragozzino, D., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3641 · Cited by 1,236
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
Kern, R. S., Nuechterlein, K. H., Green, M. F., Baade, L. E., Fenton, W. S., Gold, J. M., Keefe, R. S. E., Mesholam-Gately, R., Mintz, J., Seidman, L. J., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010043 · Cited by 744
Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis
Upthegrove, R., Manzanares-Teson, N., & Barnes, N. M. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.03.005 · Cited by 501
Rizzo, G., Veronese, M., Tonietto, M., Zanotti-Fregonara, P., Turkheimer, F. E., & Bertoldo, A. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.55 · Cited by 121
Cited by
Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Müller, N. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby024 · Cited by 648
Common brain disorders are associated with heritable patterns of apparent aging of the brain
Karolinska Schizophrenia Project (KaSP), Kaufmann, T., van der Meer, D., Doan, N. T., Schwarz, E., Lund, M. J., Agartz, I., Alnæs, D., Barch, D. M., Baur-Streubel, R., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0471-7 · Cited by 563
Self-citationCross talk: the microbiota and neurodevelopmental disorders
Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G., & Dinan, T. G. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00490 · Cited by 271
Neuroinflammation in psychiatric disorders: PET imaging and promising new targets
Meyer, J. H., Cervenka, S., Kim, M.-J., Kreisl, W. C., Henter, I. D., & Innis, R. B. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30255-8 · Cited by 270
Self-citationNeuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies
Marques, T. R., Ashok, A. H., Pillinger, T., Veronese, M., Turkheimer, F. E., Dazzan, P., Sommer, I. E. C., & Howes, O. D. (2019) · Psychological Medicine · doi:10.1017/s0033291718003057 · Cited by 213
TSPO in diverse CNS pathologies and psychiatric disease: a critical review and a way forward
Guilarte, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.003 · Cited by 173
In Vivo TSPO Signal and Neuroinflammation in Alzheimer’s Disease
Tournier, B. B., Tsartsalis, S., Ceyzériat, K., Garibotto, V., & Millet, P. (2020) · Cells · doi:10.3390/cells9091941 · Cited by 79
“DVR AD > HC: mTG, iTG, iP, Prec, Hipp, Ent, PG AD > MCI: mTG, iTG, iP, Ent, PG, Occ Positive correlations between PBR28 (combined mTG-iTG) and CDR [75] 11C-PBR28 No amyloid detection 5 HAB-MCI/AD 9 MAB-MCI/AD 3 HAB-HC 5 MAB-HC MCI/AD: (65) HC: (62) MCI/AD: 14–30 (22) HC: >29 (30) 0–90 min VT (n = 17).”
InfluentialZhang, L., Verwer, R. W. H., Zhao, J., Huitinga, I., Lucassen, P. J., & Swaab, D. F. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.08.098 · Cited by 40
Overlapping evidence of innate immune dysfunction in psychotic and affective disorders
Hughes, H. K., & Ashwood, P. (2020) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2020.100038 · Cited by 39
Metadata
- Authors
- Collste, K., Plavén-Sigray, P., Fatouros-Bergman, H., Victorsson, P., Schain, M., Forsberg, A., Amini, N., Aeinehband, S., Karolinska Schizophrenia Project (KaSP) consortium, L, F., L, F., G, E., S, E., H, F.-B., S, C., L, S., F, P., I, A., K, C., P, V., A, M., M, H., F, O., Erhardt, S., Halldin, C., Flyckt, L., Farde, L., & Cervenka, S.
- Venue
- Molecular Psychiatry
- Published
- 2017-02-14
- Volume
- 22
- Issue
- 6
- Pages
- 850-856
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2589040255
- Cited by
- 104
- References
- 6
- FWCI
- 14.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.